Last checked at 27 Jun 2016 07:00
("NetScientific" or the "Company" or the "Group")
Grant of Options to Director
London, UK - 27th June 2016 - NetScientific plc ("NetScientific", AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announced that on 24th June 2016, options over ordinary shares of 5p each were granted to Ian Postlethwaite and Stephen Smith as detailed below.
Ian Postlethwaite joined the Company on the 13th June 2016 as Chief Financial Officer, joining the Board immediately following the Company's Annual General Meeting on 15th June 2016. Stephen Smith joined the Company on 17th of February 2016 as a Non-Executive Director.
Director | Number of Options Granted | Number of OptionsHeld |
Ian Postlethwhaite | 180,000 | 180,000 |
Stephen Smith | 30,000 | 30,000 |
The options have an exercise price of 79.70 pence per share, being the average closing price for the ordinary shares over the five dealing days prior to the date on which the options were granted. The options granted to Ian Postlethwaite and Stephen Smith vest on 13th June 2019 and 17th February 2019 respectively, being three years from the dates they joined the Company.
- Ends -
For more information, please contact:
NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO
| Tel: +44 (0)20 3514 1800 |
Investec (NOMAD and broker) Gary Clarence / Daniel Adams | Tel: +44 (0)20 7597 4000 |
Consilium Strategic Communications Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton |
Tel: +44 (0)20 3709 5700 netscientific@consilium-comms.com |
About NetScientific Plc
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.